Skip to content
etf.net

Launched · SEC filings

Global X Genomics & Biotechnology ETF

GNOMNasdaqGlobal XD

$66.83−2.78 (−4.00%)

At close: Nov 2, 2026, 4:00 PM ET

D38/ 100

Rank 14 of 17 in Biotech & Genomics

D38/100Rank 14 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 69.61 to 66.83. Range 66.76 to 72.00. Use the arrow keys to read each point.68.0069.0071.0072.0010 AM12 PM2 PM4 PM
Expense ratio
0.50%
Fund size
$113M
1Y total return
+55.3%
Yield · Last 12 months
0.93%
Holdings
50
Avg volume · 30D
35K sh
52W range
low $41.16high $74.19
Launched
Filings
SEC EDGAR

The ETF.net GNOM Grade

Based on 5 of 6 pillars

D

Score 38 out of 100

Category
Biotech & Genomics⁠
Rank
14 of 17
Six-pillar profile for GNOM. Scores out of 100: Cost 38, Risk 28, Mission not scored, Tradability 50, Holdings 37, Durability 50. Strongest: Tradability (50). Weakest: Risk (28). Based on 5 of 6 pillars.

Score 38 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    D38 out of 100
    Rank 10 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D28 out of 100
    Rank 13 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    C50 out of 100
    Rank 7 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D37 out of 100
    Rank 15 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C50 out of 100
    Rank 10 of 17

Our read on GNOM

ETF.net Research

In short

DMost biotech ETFs buy the whole drug industry. GNOM buys the genome: gene editing, sequencing, genetic therapies, computational genomics. About 50 global names, one idea, no hedging.

Stated mandate

GNOM seeks to track, before expenses, the performance of the Solactive Genomics Index by investing in companies positioned to benefit from advances in genomic science, including gene editing, sequencing, genetic therapies, computational genomics, and biotechnology.

Why people hold it

  • A genuine pure play. The index targets companies tied to advances in genomic science (gene editing, sequencing, genetic therapies), not the broad pharma complex most biotech funds hold.globalxetfs.com
  • Concentrated on purpose: roughly 50 holdings, global reach. The theme drives the fund instead of being diluted by megacap drugmakers.globalxetfs.com
  • Running since 2019, it is one of the older dedicated genomics baskets, with a multi-year record through a full cycle in the theme.

Worth knowing

  • The narrow screen costs more: 0.50% a year, against 0.44% for IBB, 0.35% for XBI and 0.19% for IBBQ, which own biotech broadly.
  • Thinly traded next to the big biotech funds. Limit orders and mid-session trading matter more here than with a household-name ETF.
  • Small, clinical-stage genomics names swing hard, and with about 50 holdings there is nowhere to hide. Volatility is the price of the pure theme.

GNOM Holdings

Holdings pillarD37 out of 100Rank 15 of 17 in Biotech & GenomicsAs of
Asset class
Stocks
Holdings
50
Top-10 weight
56%
Largest holding
MRNA11.0%

Sectors

  • Health Care99.7%
  • Technology0.3%

Geography

  • United States95.30%
  • Switzerland2.55%
  • United Kingdom1.18%
  • Netherlands0.97%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueHeld by ETFs
1MRNAModerna Inc11.05%54,302$11.6M297
2TWSTTwist Bioscience Corp6.70%46,349$7.04M127
3TXG10X Genomics Inc-Class A6.38%89,189$6.71M135
4ILMNIllumina Inc6.09%23,136$6.4M331
5NTRANatera Inc5.50%14,524$5.78M239
6GHGuardant Health Inc5.22%33,707$5.49M183
71548.HKGenscript Biotech Corp4.58%895,318$4.81M74
8TECHBio-Techne Corp3.56%51,530$3.74M194
9VRTXVertex Pharmaceuticals Inc3.33%6,902$3.5M429
10QGENQiagen N.v.3.26%75,539$3.42M49
11BMRNBiomarin Pharmaceutical Inc2.94%55,751$3.09M182
12CAICaris Life Sciences Inc2.68%94,925$2.82M103
13CRSPCrispr Therapeutics AG2.63%53,513$2.76M82
14VCYTVeracyte Inc2.57%61,382$2.7M143
15BNTXBiontech Se-Adr2.54%27,809$2.67M33

Showing 1–15 of 50 holdings

GNOM Performance

Launched Apr 5, 2019

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
GNOM$15,533
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. GNOM $15,533. SPY $11,199. Use the arrow keys to read each point.$10,000$12,500$15,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for GNOM. Periods over one year show the average yearly return.
PeriodGNOM
Year to date+53.3%
1 month−1.2%
3 months+28.5%
1 year+55.3%
3 yearsper year+25.9%
5 yearsper year−3.8%
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for GNOM
YearReturn barGNOM
2026 YTD+53.3%
2025+18.7%

GNOM in the news

GNOM Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.93%Last 12 months
Payout per share
$0.65Last 12 months
Last payment
$0.06 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Twice a year

Distribution history

2020–2026

One bar per payment. 5 payments from 2020 to 2026 YTD. Dec 30, 2020 $0.13; Dec 30, 2021 $0.03; Jun 27, 2025 $0.03; Dec 30, 2025 $0.59; Jun 29, 2026 $0.06. Use the arrow keys to read each point.2020202120222023202420252026YTD
Ex-datePay dateAmount per share
Jun 29, 2026Jul 7, 2026$0.06
Dec 30, 2025Jan 7, 2026$0.59
Jun 27, 2025Jul 7, 2025$0.03
Dec 30, 2021Jan 7, 2022$0.03
Dec 30, 2020Jan 8, 2021$0.13

$10,000 in GNOM 5 years ago paid $79.58 in dividends.

GNOM Risk

Risk pillarD28 out of 100Rank 13 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
30.0%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.77
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−68.9%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.60
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

GNOM Cost

Compare GNOM and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$6,027

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • GNOM 0.50%

    $9,979

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • GNOM 0.50%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530GNOM $9,979IBBQ $3,952

Year by year

YearGNOMIBBQOverpaying
10$900$347$553
20$3,460$1,351$2,109
30$9,979$3,952$6,027

Other funds in Biotech & Genomics

See others